Life Sciences

The Parker Institute for Cancer Immunotherapy

THE OPPORTUNITY

Each year worldwide, there are 14 million new cancer cases and 8.2 million cancer deaths. And without a major breakthrough, by 2030 each year there will be 21.7 million new cancer cases and 13 million cancer deaths worldwide.

Cancer immunotherapy offers a new way forward. It is one of the most important medical advances of our time, and the first approach with the potential to generate long-lasting regressions for all types and stages of cancer. It harnesses the body’s own powerful immune system and mobilizes its highly refined disease-fighting arsenal to eliminate cancer cells. Cancer immunotherapies overwhelm cancer’s evasive strategies, to ensure that a powerful, precise and adaptable immune attack is focused on tumors anywhere in the body.


The Program

The Parker Institute for Cancer Immunotherapy is an unprecedented collaboration between the country’s leading immunologists and cancer centers — Memorial Sloan Kettering Cancer Center, Stanford University, UCLA, UCSF, the University of Texas MD Anderson Cancer Center, and the University of Pennsylvania — for the first time unifying the research programs, intellectual property licensing, data collection, and clinical trials across multiple centers under the umbrella of a single non-profit biomedical research organization.

The Parker Institute’s goal is to accelerate the development of breakthrough immune therapies capable of turning cancer into a curable disease by ensuring the coordination and collaboration of the field’s top researchers, and quickly turning their findings into patient treatments.

Over 40 laboratories and more than 300 researchers and immunologists from the country’s leading cancer centers are part of the network. Each Parker Institute research center receives comprehensive funding, and access to dedicated research, clinical resources and the key technologies needed to accelerate development in cancer immunotherapy. In a unique agreement, the administration of all intellectual property will be shared, enabling all researchers to have immediate access to a broad swath of core discoveries. A scientific steering committee of the field’s leaders will set a research agenda and coordinate world-class research teams focused on the most pressing and promising scientific questions.

The Parker Institute was created through a $250 million grant from the Parker Foundation.

Leadership

Dr. Jeffrey Bluestone, PhD CEO

  • University of California, San Francisco (UCSF)

Dr. Jim Allison, PhD

  • The University of Texas MD Anderson Cancer Center

Dr. Carl June, MD

  • The University of Pennsylvania

Dr. Lewis Lanier, PhD

  • University of California, San Francisco (UCSF)

Dr. Crystal Mackall, MD

  • Stanford School of Medicine

Dr. Antoni Ribas, MD, PhD

  • University of California, Los Angeles (UCLA)

Dr. Jedd Wolchok, MD

  • Memorial Sloan Kettering Cancer Center

Website

parkerici.org